Fludeoxyglucose F 18 in Detecting Lymph Node Metastasis in Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed by Surgery

• Status: Completed
• Trial end date: 2017-07-26
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Diagnostic procedures using fludeoxyglucose F 18 and a surgical probe may help find lymph node metastases in patients with early-stage non-small cell lung cancer.

PURPOSE: This clinical trial is studying how well fludeoxyglucose F 18 works in detecting lymph node metastasis in patients with stage I or stage II non-small cell lung cancer that can be removed by surgery.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Roswell Park Cancer Institute
• Treatments: Fluorodeoxyglucose F18

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of non-small cell lung cancer

• Stage I-II disease

• Resectable disease

• Planning to undergo surgical resection

• No tumors that are not fludeoxyglucose F 18 (FDG)-avid on PET scan

PATIENT CHARACTERISTICS:

• Not pregnant

• Negative pregnancy test

• Fertile patients must use effective contraception

• No previous allergic reaction to fludeoxyglucose F 18

• No contraindication to a pulmonary lobectomy and lymphadenectomy

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics